





ASSESSING THE PERFORMANCE OF AUTOMATED ANTI-RED BLOOD CELL ANTIBODIES TITRATION BY COLUMN **AGGLUTINATION TECHNOLOGY ON THE IH-500 SYSTEM (Bio-Rad®)**


Jenny BEAUD¹, Andréa ADIOGO¹, Stéphanie HUGUET-JACQUOT¹, Hélène DELABY¹, Agnès MAILLOUX¹, <u>Cécile TOLY-NDOUR¹</u>

¹ Unité Fonctionnelle d'expertise en Immuno-Hémobiologie Périnatale, Centre National de Référence en Hémobiologie Périnatale (CNRHP), Pôle de Biologie Médicale et Pathologie, Hôpital St Antoine, Paris, France

Background : In France, since May 2018, the legislation does not promote anymore the use of the reference tube method for titration of anti-red blood cells antibodies. This opened the way to the use of newly developed automated anti-red blood cells antibodies quantitation by column agglutination technology.

<u>Aims:</u> We wanted to assess the performance of titration and scoring by the ID-gel test on the IH-500 system (Bio-Rad®) and to compare it with the performance established for the reference tube method, used in our lab since decades. Another objective of the study was to determine titer thresholds for the gel method, to trigger fetal monitoring by ultrasounds and measurements of the peak systolic velocity in the middle cerebral artery.

Methods: The antibody titer is defined as the greatest dilution of the plasma/serum at which a detectable hemagglutination is still visible.



Results:

An home-made internal quality control (IQC) prepared and calibrated using the international anti-D Standard (01/572) was used to determine the intraassay and interassay imprecisions, regarding the score and the titer results.

Figure 1: Intra and interassay imprecisions of automated and manual tube and gel titration methods determined with an home-made anti-D (RH1) internal quality control

| / . | | \mathbf{N} \mathbf{I} \mathbf{I} \mathbf{O} \mathbf{O} \mathbf{I} | |
|-----|--|-----------------------------------------------------------------------------------|------|

| | Intra | assay impre | cision | Interassay imprecision | | | | |
|---------------------------------------|-------|----------------------------|----------------------------|------------------------|----------------------------|----------------------------|--|--|
| Titration method | N= | Titer results (CV %) | Score results (CV %) | N= | Titer results (CV %) | Score results (CV %) | | |
| Tube manual dilution | 19 | 9,2 | 11,5 | 29 | 10,3 | 20,9 | | |
| Tube automated dilution | 26 | 0 | 6,1 | 30 | 3,7 | 6,4 | | |
| Gel manual dilution | 19 | 6,3 | 6,4 | 8 | 10,1 | 7,9 | | |
| Gel automated dilution (IH-500) | 20 | 0 | 1,25 | 9 | 0 | 1,9 | | |

The intra and interassay imprecisions of the titer/score determined by automated gel method show a low coefficient of variation (CV) (<2%) compared to non-automated gel

(value of the IQC titer = 32 (tube method) / 128 (gel method)) The CV (coefficient of variation) for titer results were calculated based on the number of the last positive dilution with the respecting equivalence titer 2 = dilution 1, titer 4 = dilution 2, titer 8 = dilution 3, titer 16 = dilution 4, titer 32 = dilutions 5, titer 64 = dilution 6, titer 128 =dilution 7, titer 256 =dilution 8, titer 512 =dilution 9, titer 1024= dilution 10, titer 2048 = dilution 11

method (6 to 8 %) or tube methods (6 to 20 %).

Patients samples for testing were chosen during the 2-months assay period, regarding the specificity of the antibodies and the tube titer in order to cover a wide range of situations. Comparison of the results obtained from the same clinical samples with both methods was carried out.

| | Ν | N with identical titer in both methods | N with a higher titer with the tube method | N with a higher titer with the gel method | mean of the difference (gel-tube) (number of dilutions) |
|------------------|-----|-------------------------------------------|-----------------------------------------------|----------------------------------------------|---------------------------------------------------------------|
| anti-D (RH1) | 26 | 0 | 0 | 26 | 3,96 |
| Anti-C (RH2) | 3 | 1 | 0 | 2 | 1,33 |
| Anti-E (RH3) | 11 | 1 | 0 | 10 | 2,27 |
| Anti-c (RH4) | 21 | 2 | 0 | 19 | 3,29 |
| Anti-e (RH5) | 2 | 0 | 0 | 2 | 3,5 |
| Anti-Cw (RH8) | 3 | 0 | 0 | 3 | 1,67 |
| Anti-Kell (KEL1) | 16 | 2 | 1 | 13 | 1,81 |
| Anti-Kpa (KEL3) | 1 | 0 | 0 | 1 | 2 |
| Anti-Jka (JK1) | 8 | 1 | 0 | 7 | 1,38 |
| Anti-Jkb (JK2) | 3 | 1 | 0 | 2 | 1 |
| Anti-Fya (FY1) | 2 | 0 | 0 | 2 | 2,5 |
| Anti-Fyb (FY2) | 2 | 1 | 0 | 1 | 1 |
| Anti-M (MNS1) | 15 | 5 | 1 | 9 | 1,13 |
| anti-S (MNS3) | 4 | 1 | 0 | 3 | 1,75 |
| anti-s (MNS4) | 2 | 0 | 0 | 2 | 2 |
| anti-U (MNS5) | 3 | 0 | 0 | 3 | 3,33 |
| TOTAL | 122 | 15 | 2 | 105 | |

| Anti-D (RH1) | n= 26 | | | | | | | | | | | | |
|---------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Gel titer | | | | | | | | | | | | |
| tube titer | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | 1024 | 2048 | > 2048 |
| <2 | | | | | 1 | | | | | | | | |
| 2 | | | | 1 | | | | | | | | | |
| 4 | | | | | | 1 | 1 | | 1 | | | | |
| 8 | | | | | | | | 1 | 2 | | | | |
| 16 | | | | | | | | | 2 | | 1 | | |
| 32 | | | | | | | | | | 2 | 2 | | |
| 64 | | | | | | | | | | 2 | 2 | | |
| 128 | | | | | | | | | | 1 | | | 1 |
| 256 | | | | | | | | | | | | | 2 |
| > 256 | | | | | | | | | | | | | 3 |
| Anti-K (KEL1) | n= 16 | | | | | | | | | | | | |
| | Gel titer | | | | | | | | | | | | |
| tube titer | 1 | 2 | 4 | 8 | 16 | 32 | 64 | 128 | 256 | 512 | 1024 | 2048 | > 2048 |
| <2 | 1 | | 2 | | | | | | | | | | |
| 2 | | 1 | | | | | | | | | | | |
| Δ | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| 8 | | | | | | | | | | | | | |
| | | | | | | 1 | | | | | | | |
| 8 | | | | | 1 | 1 | | | 1 | | | | |
| 8 16 | | | | | 1 | 1 | | | 1 | 2 | | | |
| 8 16 32 | | | | | 1 | 1 | | | | 2 | | | |
| | tube titer <2 2 4 8 16 32 64 128 256 > 256 > 256 Anti-K (KEL1) tube titer <2 2 | <2 2 4 4 8 16 32 64 128 256 256 Anti-K (KEL1) n= 16 tube titer 1 2 1 | tube titer 1 2 <2 $<$ $<$ 2 $<$ $<$ 4 $<$ $<$ 8 $<$ $<$ 16 $<$ $<$ 32 $<$ $<$ 64 $<$ $<$ 128 $<$ $<$ 256 $<$ $<$ Anti-K (KEL1) n= 16 $<$ tube titer 1 2 <2 1 2 2 1 2 <2 1 2 | tube titer 1 2 4 <2 $<$ $<$ $<$ 2 $<$ $<$ $<$ 4 $<$ $<$ $<$ 4 $<$ $<$ $<$ 8 $<$ $<$ $<$ 16 $<$ $<$ $<$ 32 $<$ $<$ $<$ 64 $<$ $<$ $<$ 128 $<$ $<$ $<$ 256 $<$ $<$ $<$ Anti-K (KEL1) n= 16 $<$ $<$ tube titer 1 2 4 <2 1 2 4 | tube titer 1 2 4 8 <2 $<$ $<$ $<$ $<$ 2 $<$ $<$ $<$ $<$ 4 $<$ $<$ $<$ $<$ 8 $<$ $<$ $<$ $<$ 16 $<$ $<$ $<$ $<$ 32 $<$ $<$ $<$ $<$ 64 $<$ $<$ $<$ $<$ 128 $<$ $<$ $<$ $<$ 256 $<$ $<$ $<$ $<$ Anti-K (KEL1) $n=16$ $<$ $<$ $<$ tube titer 1 2 4 8 <2 1 2 2 $<$ 2 1 2 2 $<$ | tube titer 1 2 4 8 16 <2 - - 1 1 2 - - 1 - 4 - - 1 - 8 - - - - 16 - - - - 32 - - - - 64 - - - - 128 - - - - 256 - - - - 256 - - - - tube titer 1 2 4 8 16 - - - - - 1 2 4 8 16 - - - - - 2 1 2 - - - - 2 1 - 2 - - - - - 1 2 1 | tube titer 1 2 4 8 16 32 <2 1 1 1 1 2 1 1 1 1 2 1 1 1 1 4 1 1 1 1 4 1 1 1 1 4 1 1 1 1 8 1 1 1 1 16 1 1 1 1 32 1 1 1 1 64 1 1 1 1 128 1 1 1 1 256 1 1 1 1 Anti-K (KEL1) n= 16 1 1 1 1 2 4 8 16 32 <26 1 2 4 8 16 32 <20 1 2 4 8 16 32 <2 1 2 4 8 <td>Gel tite tube titer 1 2 4 8 16 32 64 <2 . . 1 . . 1 . . 2 . . 1 . . 1 . . 4 . . . 1 1 1 . . 4 1 1 . 4 </td> <td>Image: constraint of the state of the</td> <td>ube titer 1 2 4 8 16 32 64 128 256 <2 $<$ $<$ $<$ 1 $<$ $<$ $<$ 2 $<$ $<$ 1 $<$ $<$ $<$ $<$ 4 $<$ $<$ $<$ 1 1 $<$ $<$ 4 $<$ $<$ $<$ $<$ 1 1 1 1 8 $<$ $<$ $<$ $<$ $<$ $<$ 1 1 2 32 $<$ $<$ $<$ $<$ $<$ $<$ $<$ 2 32 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ 2 64 $<$ $<$</td> <td>Gel titer tube titer 1 2 4 8 16 32 64 128 256 512 <2 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 4 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 8 1 1 1 1 2 1 16 1 1 1 1 2 2 64 1 1 1 1 1 1 256 1 1 1 1 1 1 256 1 1 1 1 1 1 <</td> <td>tube titer 1 2 4 8 16 32 64 128 256 512 1024 <2 $<$ $<$</td> <td>Gel titer tube titer 1 2 4 8 16 32 64 128 256 512 1024 2048 <2</td> 1 1 | Gel tite tube titer 1 2 4 8 16 32 64 <2 . . 1 . . 1 . . 2 . . 1 . . 1 . . 4 . . . 1 1 1 . . 4 1 1 . 4 | Image: constraint of the state of the | ube titer 1 2 4 8 16 32 64 128 256 <2 $<$ $<$ $<$ 1 $<$ $<$ $<$ 2 $<$ $<$ 1 $<$ $<$ $<$ $<$ 4 $<$ $<$ $<$ 1 1 $<$ $<$ 4 $<$ $<$ $<$ $<$ 1 1 1 1 8 $<$ $<$ $<$ $<$ $<$ $<$ 1 1 2 32 $<$ $<$ $<$ $<$ $<$ $<$ $<$ 2 32 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ 2 64 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ | Gel titer tube titer 1 2 4 8 16 32 64 128 256 512 <2 1 1 1 1 1 1 1 1 2 1 1 1 1 1 1 1 1 4 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 1 8 1 1 1 1 1 1 1 1 8 1 1 1 1 2 1 16 1 1 1 1 2 2 64 1 1 1 1 1 1 256 1 1 1 1 1 1 256 1 1 1 1 1 1 < | tube titer 1 2 4 8 16 32 64 128 256 512 1024 <2 $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ $<$ | Gel titer tube titer 1 2 4 8 16 32 64 128 256 512 1024 2048 <2 |

Figure 2: Comparison of the titer results obtained with automated tube method and with the IH-500 gel method from the same clinical samples (N = 122)

On the 122 samples tested: 105 have higher titer values with the column agglutination technology, 15 have equal values and 2 have lower values. The **highest differences** (more than 2 to 3 dilutions higher; highlighted in orange) were seen for antibodies directed against RH system antigens . Among the other specificities, Anti-K (KEL1) and anti-M (MNS1) antibodies show the most samples with equal or lower titers compared to the tube method (highlighted in green)

Figure 3:

Determination of gel thresholds for triggering ultrasonographical fetal surveillance. Comparison of the titer results obtained with automated tube and IH-500 gel methods from each sample used containing anti-D (RH1) [A] and anti-K (KEL1) [B] antibodies

For all **anti-D (RH1) antibodies** samples, the gel titer was higher compared to the corresponding tube titer. The tube threshold of 16 used since decades in our lab (see yellow line) may be extrapolated to at least 3 dilutions higher for the gel **method** - i.e. 128 if we take into account the measurement incertainty. For anti-K (KEL1) antibodies, gel titers were equal, slightly higher or even lower depending on the sample tested. The tube threshold of 16 used in our lab may be also relevant for gel titers.

Further testing on more samples are required.

> 256

Conclusions :

Automated anti-red blood cell antibodies titration by column agglutination technology on IH-500 system shows better intra and interassay CVs compared to the tube method. It is explained by the fully automated process that includes the reading step. Titer results are almost always higher with the gel technology.

Thus, it seems possible to safely extrapolate the titer thresholds defined for anti-red blood cells antibodies by the tube method to the gel method. However, based on future clinical studies and fetal/neonatal outcomes, it would probably be necessary to increase these thresholds, at least for anti-RH antibodies, in order to avoid heavy, expensive, stressful and useless monitoring of some pregnancies.